Targeting p73 in cancer

详细信息    查看全文

• 作者：Anna-Maria Maas¹ ; Anne Catherine Bretz¹ ; Elisabeth Mack ; Thorsten Stiewe ; ^{thorsten.stiewe@staff.uni-marburg.de}
• 关键词：Tumor suppressor genes ; p73 ; p53 ; Molecular therapy
• 刊名：Cancer Letters
• 出版年：2013
• 出版时间：28 May, 2013
• 年：2013
• 卷：332
• 期：2
• 页码：229-236
• 全文大小：313 K

文摘

p73 is a member of the p53 family of tumor suppressors. Transactivating isoforms of p73 (TAp73) have p53-like, anti-proliferative and pro-apoptotic activities that are crucial for an efficient chemotherapy response. In line with this, genetic studies in mice have confirmed that TAp73 acts as a tumor suppressor. However, in contrast to p53, which is commonly inactivated in human cancer by point mutations, the TP73 gene is almost never mutated. Instead, the tumor suppressor activity of TAp73 is inhibited through a variety of mechanisms including epigenetic silencing and complex formation with inhibitory proteins. All these mechanisms have in common that they are in principle reversible and therefore amenable to therapeutic intervention. Here, we will review how tumor cells control the tumor suppressor activity of TAp73 and discuss possible strategies targeting p73 for reactivation.